Seattle Genetics, Inc. announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets.
LIVE access on Thursday, July 26, 2018
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
- Telephone 877-260-1479 (domestic) or +1 334-323-0522 (international); conference ID 6908320
- Webcast available at www.seattlegenetics.com in the Investors section
REPLAY access
- Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, July 26, 2018 through 5:00 p.m. PT on Monday, July 30, 2018 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 6908320
- Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180628005282/en/
Contacts
Seattle Genetics, Inc.
Investors
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
or
Media
Monique Greer, 425-527-4641
mgreer@seagen.com
Source: Seattle Genetics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180628005282/en
